Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Indagine sull'Effetto Antinfiammatorio della Ketamina nella Chirurgia Cardiaca

31 ottobre 2026 aggiornato da: turgay atay, Konya City Hospital

Investigazione dell'Effetto Antinfiammatorio della Ketamina in Chirurgia Cardiaca: Studio Controllato Randomizzato

Background:

Cardiac surgery with cardiopulmonary bypass induces a systemic inflammatory response that may contribute to postoperative complications. Ketamine has been investigated for its potential immunomodulatory effects. This randomised controlled trial evaluated the effects of intraoperative ketamine administration on postoperative inflammatory biomarkers and clinical outcomes in patients undergoing elective cardiac surgery.

Methods:

This single-centre, randomised, controlled, single-blind trial was conducted at Necmettin Erbakan University Meram Faculty of Medicine Hospital, Türkiye. Between 30 October 2022 and 30 March 2023, 177 patients were assessed for eligibility, of whom 166 provided written informed consent and were randomised to the ketamine (n = 83) or control (n = 83) group.

All patients received standard general anaesthesia. In addition, the ketamine group received an intravenous ketamine bolus of 1 mg/kg at induction, followed by a continuous intraoperative infusion of 2.4 mg/kg/h.

The two primary outcomes specified in the original study protocol dated 5 September 2022 were neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein (CRP), measured on postoperative day 1. The prespecified secondary outcomes included postoperative pain intensity assessed using the Numeric Rating Scale (NRS) and Prince Henry Hospital Pain Score (PHHPS), time to extubation, intensive care unit length of stay, and hospital length of stay.

Additional inflammatory parameters, including platelet-to-lymphocyte ratio (PLR), systemic inflammatory response index (SIRI), systemic immune-inflammation index (SII), and derived measures of perioperative biomarker changes, were evaluated in post hoc exploratory analyses. Additional clinical outcomes, including 28-day all-cause mortality, were also assessed on an exploratory basis.

Six randomised patients (three per group) died before postoperative day 1 biomarker measurements could be obtained. Consequently, 160 patients (80 per group) were included in the primary biomarker analyses, while all 166 randomised patients were included in the 28-day mortality analysis.

The study was retrospectively registered at ClinicalTrials.gov on 30 March 2026, after completion of recruitment and data collection.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Participants and Study Design

This was a single-centre, randomised, controlled, single-blind clinical trial conducted at Necmettin Erbakan University Meram Faculty of Medicine Hospital, Türkiye. The study included adults aged 18-80 years who were scheduled to undergo elective cardiac surgery, were able to provide written informed consent, and could reliably communicate their symptoms to the research team.

Exclusion criteria included contraindications to anaesthesia; cognitive impairment or communication difficulties; end-stage renal disease requiring haemodialysis; pregnancy or breastfeeding; known allergy to ketamine; left ventricular ejection fraction below 35%; emergency or repeat cardiac surgery; significant cardiac arrhythmia; morbid obesity; psychiatric disorders; hepatic insufficiency; use of anti-inflammatory medications; preoperative white blood cell count ≥15 × 10³/µL; C-reactive protein (CRP) ≥30 mg/L; and refusal to participate.

Between 30 October 2022 and 30 March 2023, 177 patients were assessed for eligibility. Eleven individuals were excluded before providing written research consent and before randomisation. Consequently, 166 patients provided written informed consent and were randomised to the ketamine group (n = 83) or the control group (n = 83).

Six randomised patients (three in each group) died intraoperatively or within the first 24 postoperative hours, before postoperative day 1 inflammatory biomarker measurements could be obtained. Therefore, the primary biomarker analyses included 160 patients (80 per group). All 166 randomised patients were included in the 28-day all-cause mortality analysis.

The original study protocol (Version 1.0, dated 5 September 2022) received ethics committee approval on 14 September 2022 (decision no. 2022/926). Authorisation to initiate the clinical trial was granted by the Turkish Medicines and Medical Devices Agency on 26 October 2022 (application no. 22-AKD-189).

The study was retrospectively registered at ClinicalTrials.gov on 30 March 2026, after completion of recruitment and data collection.

Randomisation and Blinding

Patients were randomly allocated to the ketamine or control group using a sealed, opaque envelope method involving the drawing of lots, as specified in the original study protocol. Allocation was performed by an investigator who was not otherwise involved in the study.

Patients were blinded to their treatment allocation. The anaesthesia team administering the study intervention was not blinded.

Anaesthesia Protocol

Upon arrival in the operating room, all patients received intravenous premedication with midazolam (1 mg) and fentanyl (50 µg). Standard monitoring, including electrocardiography and peripheral oxygen saturation, was applied. Invasive arterial blood pressure monitoring was established by radial artery catheterisation using a 20-gauge cannula under local anaesthesia.

All weight-based drug doses were calculated using adjusted body weight.

Anaesthesia was induced with intravenous midazolam (0.1 mg/kg), fentanyl (3 µg/kg), and rocuronium (0.6 mg/kg) in both groups.

In addition to the standard induction regimen, patients allocated to the ketamine group received an intravenous ketamine bolus of 1 mg/kg at induction, followed by a continuous intravenous infusion of 2.4 mg/kg/h throughout the intraoperative period. Patients allocated to the control group received standard anaesthesia without additional ketamine administration.

Following adequate muscle relaxation and induction of anaesthesia, endotracheal intubation was performed. A central venous catheter was subsequently inserted through the right internal jugular vein.

Intraoperative analgesic and haemodynamic management was guided by haemodynamic parameters and Surgical Pleth Index (SPI) monitoring. Baseline heart rate, systolic arterial pressure, diastolic arterial pressure, and mean arterial pressure were recorded before induction after premedication. Additional haemodynamic measurements were obtained immediately before intubation, every minute during the first five minutes after intubation, and subsequently at 10-minute intervals throughout surgery.

Anaesthesia was maintained using intravenous remifentanil (0.1-0.3 µg/kg/min) and inhaled sevoflurane (0.5-1 minimum alveolar concentration). An SPI target range of 40-60 was used together with haemodynamic variables to guide intraoperative management. Changes of approximately 20-30% from baseline haemodynamic values were considered clinically relevant.

Hypotension was managed using ephedrine or norepinephrine, as clinically indicated. Hypertension was managed by adjusting the administration of remifentanil and sevoflurane.

Approximately one hour before the end of surgery, all patients received intravenous morphine (0.1 mg/kg) for postoperative analgesia. Intravenous paracetamol (10-15 mg/kg) was administered every eight hours during the postoperative period.

Following surgery, patients were transferred to the intensive care unit (ICU) under mechanical ventilation. Postoperative sedoanalgesia was maintained using remifentanil (0.05-0.1 µg/kg/min) and dexmedetomidine (0.5-1 µg/kg/h) infusions until extubation criteria were met.

Patients were assessed for weaning from mechanical ventilation according to clinical status, blood gas findings, haemodynamic stability, and normothermia. Extubation was performed when the relevant clinical criteria had been fulfilled.

Post-extubation rescue analgesia consisted of intravenous tramadol (1 mg/kg, generally 50-100 mg), administered when required.

Outcome Measures

The original ethics-approved study protocol, dated 5 September 2022, specified two primary outcomes and five secondary outcome measures.

Prespecified primary outcomes

  1. Neutrophil-to-lymphocyte ratio (NLR), measured on the morning of postoperative day 1.
  2. C-reactive protein (CRP) concentration, measured on the morning of postoperative day 1.

NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count. CRP was measured in mg/L using routine laboratory testing.

Prespecified secondary outcomes

  1. Postoperative pain intensity assessed using the Numeric Rating Scale (NRS).
  2. Postoperative pain intensity assessed using the Prince Henry Hospital Pain Score (PHHPS).
  3. Time to tracheal extubation.
  4. Length of ICU stay.
  5. Length of hospital stay.

Postoperative pain was assessed using NRS and PHHPS during the early postoperative period. The NRS ranges from 0 (no pain) to 10 (worst imaginable pain). PHHPS is a categorical pain assessment scale ranging from 0 to 4.

Extubation time was recorded in hours, ICU length of stay in hours, and hospital length of stay in days.

Post hoc exploratory outcomes and analyses

Additional inflammatory indices, derived biomarker measures, and selected clinical outcomes were evaluated in analyses introduced after the original study protocol had been established.

Routine preoperative and postoperative day 1 laboratory measurements were used to assess white blood cell, neutrophil, lymphocyte, and platelet counts, together with derived inflammatory indices including platelet-to-lymphocyte ratio (PLR), systemic inflammatory response index (SIRI), and systemic immune-inflammation index (SII).

The derived indices were calculated as follows:

  • NLR = neutrophil count / lymphocyte count
  • PLR = platelet count / lymphocyte count
  • SIRI = neutrophil count × monocyte count / lymphocyte count
  • SII = platelet count × neutrophil count / lymphocyte count

Perioperative changes in inflammatory markers were calculated as postoperative minus preoperative values (delta values). Biomarker indices were calculated as postoperative-to-preoperative ratios.

Additional exploratory clinical assessments included intraoperative haemodynamic variables, vasoactive and inotropic support, additional postoperative analgesic requirements, and 28-day all-cause mortality.

Intraoperative vasoactive and inotropic support was quantified using the vasoactive-inotropic score (VIS), calculated as:

VIS = dopamine dose + dobutamine dose + 100 × epinephrine dose + 100 × norepinephrine dose + 10 × milrinone dose + 10,000 × vasopressin dose.

Catecholamine and milrinone doses were expressed in µg/kg/min, and vasopressin in U/kg/min. VIS during cardiopulmonary bypass and at the end of surgery was recorded.

The additional exploratory outcomes and derived analyses were not prespecified as primary outcomes in the original ethics-approved protocol and should be interpreted as hypothesis-generating.

Sample Size Calculation

The original sample size calculation was performed using G*Power before patient recruitment. The documented calculation, dated 15 June 2022, assumed a standardised effect size (Cohen's d) of 0.5537, a one-sided significance level of 0.05, and 95% statistical power, yielding a minimum required sample size of 144 participants (72 per group).

The original study protocol (Version 1.0, dated 5 September 2022) specified a target sample size of 160 participants (80 per group). Ultimately, 166 participants were randomised.

No formal pilot study was conducted to determine the sample size. The source used to derive the assumed effect size of 0.5537 and the specific primary outcome underlying the original calculation could not be verified retrospectively. The previously entered registry statement indicating that the calculation was based on a pilot study of 10 participants per group was incorrect and has been corrected retrospectively.

No adjustment for multiple testing of the two co-primary outcomes was incorporated into the documented sample size calculation.

Statistical Analysis

The original statistical analyses were performed using IBM SPSS Statistics (version 23.0; IBM Corp., Armonk, NY, USA). Additional post hoc analyses and statistical verification were conducted using Python with the SciPy and statsmodels packages.

Continuous variable distributions were assessed using the Shapiro-Wilk test. Normally distributed variables were presented as mean ± standard deviation, whereas non-normally distributed variables were reported as median (interquartile range). Categorical variables were presented as counts and percentages.

Between-group comparisons were performed using independent-samples t-tests for normally distributed continuous variables and Mann-Whitney U tests for non-normally distributed variables. Categorical variables were compared using Pearson's chi-square test or Fisher's exact test, as appropriate.

The reported hypothesis tests were two-sided, with p < 0.05 considered statistically significant in the original analyses. Although the original sample size calculation used a one-sided significance level, the reported outcome analyses were conducted using two-sided tests.

The original protocol specified postoperative day 1 NLR and CRP as the two primary outcomes without a prespecified adjustment for multiple testing. A Bonferroni-adjusted threshold of p < 0.025 was subsequently considered as a post hoc sensitivity analysis.

Additional post hoc analyses of covariance (ANCOVA) were conducted separately for postoperative NLR and CRP, using treatment group as the independent variable and the corresponding preoperative biomarker value as a covariate. Adjusted between-group differences and 95% confidence intervals were estimated using heteroskedasticity-robust (HC3) standard errors.

Further sensitivity analyses were performed using natural logarithm-transformed postoperative biomarker values, adjusted for the corresponding natural logarithm-transformed preoperative values. Treatment coefficients from these models were exponentiated and expressed as adjusted ketamine-to-control ratios with 95% confidence intervals.

Additional inflammatory indices, derived measures, and clinical outcomes introduced after data collection were analysed on an exploratory basis. Their findings were interpreted as hypothesis-generating rather than confirmatory.

The analyses of postoperative day 1 NLR and CRP were restricted to 160 patients with available measurements (80 per group). Six randomised patients died before these measurements could be obtained. Because these missing biomarker outcomes arose from death, they could not be assumed to be missing at random.

All 166 randomised patients (83 per group) were included in the 28-day mortality analysis.

Retrospective Registry Clarification

This study was retrospectively registered on 30 March 2026, after completion of recruitment and data collection. The initial registry record included outcome measures and classifications that were not fully aligned with the original ethics-approved protocol dated 5 September 2022.

The primary and secondary outcome classifications have been clarified with reference to the original protocol. Additional inflammatory indices, derived measures, and exploratory clinical analyses were not prospectively registered as primary or secondary outcomes.

These clarifications describe the differences between the original protocol and the retrospectively entered registry information. They do not constitute prospectively registered amendments to the study design.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

166

Fase

  • Fase 4

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Konya
      • Meram, Konya, Turchia (Türkiye), 42000
        • Necmettin Erbakan University Meram Faculty of Medicine Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 80 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria

  • Patients aged 18-80 years.
  • Scheduled to undergo elective cardiac surgery.
  • Able to provide informed consent.
  • Able to reliably communicate symptoms to the research team. Exclusion Criteria
  • Contraindications to anesthesia.
  • Cognitive impairment or communication barriers.
  • End-stage renal failure (receiving routine hemodialysis).
  • Pregnancy or breastfeeding.
  • Known allergy to ketamine.
  • Ejection fraction (EF) <35%.
  • Emergency or repeat surgery.
  • Arrhythmia.
  • Morbid obesity.
  • Psychiatric disorders.
  • Hepatic failure.
  • Use of anti-inflammatory medications.
  • Preoperative white blood cell count (leukocyte) ≥15 × 10³/µL.
  • C-reactive protein (CRP) ≥30 mg/L.
  • Declined to participate in the study

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Nessun intervento: control group

Standard treatment was administered to all patients.

Comparatore attivo: ketamine group

In addition to standard treatment, ketamine was administered at a dose of 1 mg/kg during induction and as a continuous infusion at 2.4 mg/kg/h

In addition to standard treatment, ketamine was administered at a dose of 1 mg/kg during induction and as a continuous infusion at 2.4 mg/kg/h

Altri nomi:
  • Ketamina cloridrato, Ketalar

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Postoperative Day 1 Neutrophil-to-Lymphocyte Ratio (NLR)
Lasso di tempo: Postoperative day 1 (morning)

NLR was calculated as the absolute neutrophil count divided by the absolute lymphocyte count, using routine blood tests obtained on the morning of postoperative day 1.

Postoperative day 1 (morning)
Postoperative Day 1 C-Reactive Protein (CRP)
Lasso di tempo: Postoperative day 1 (morning)

Serum C-reactive protein (CRP) concentration was measured in mg/L using routine blood tests obtained on the morning of postoperative day 1.

Postoperative day 1 (morning)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Length of ICU Stay
Lasso di tempo: From ICU admission to ICU discharge (up to 28 days)

Duration of stay in the intensive care unit, measured in hours.

From ICU admission to ICU discharge (up to 28 days)
Length of Hospital Stay
Lasso di tempo: From the date of surgery to hospital discharge (up to 28 days)

Total duration of hospitalization following surgery, measured in days.

From the date of surgery to hospital discharge (up to 28 days)
Postoperative Pain Score (NRS)
Lasso di tempo: First 24 hours after extubation

Pain severity assessed using the Numeric Rating Scale ranging from 0 (no pain) to 10 (worst pain).

First 24 hours after extubation
Postoperative Pain Score (PHHPS)
Lasso di tempo: Within the first 24 hours after extubation

Postoperative pain intensity and patient comfort were assessed using the Prince Henry Hospital Pain Score (PHHPS), a categorical scale ranging from 0 to 4, where 0 indicates no pain on coughing, 1 indicates pain on coughing but not on deep breathing, 2 indicates pain on deep breathing but not at rest, 3 indicates mild pain at rest, and 4 indicates severe pain at rest.

Within the first 24 hours after extubation
Time to Extubation
Lasso di tempo: From the end of surgery to tracheal extubation (within 48 hours postoperatively)

Time from the end of surgery to successful tracheal extubation, measured in hours.

From the end of surgery to tracheal extubation (within 48 hours postoperatively)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Turgay Atay, Konya City Hospital
  • Direttore dello studio: gamze sarkılar, Necmettin Erbakan University Meram Faculty of Medicine Hospital

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

30 ottobre 2022

Completamento primario (Effettivo)

30 marzo 2023

Completamento dello studio (Effettivo)

30 maggio 2023

Date di iscrizione allo studio

Primo inviato

30 marzo 2026

Primo inviato che soddisfa i criteri di controllo qualità

15 aprile 2026

Primo Inserito (Effettivo)

17 aprile 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

3 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

31 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 2022/926

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

De-identified individual participant data underlying the published study results, together with an accompanying data dictionary, may be made available to qualified researchers upon reasonable request, subject to applicable institutional and ethical approvals and execution of an appropriate data-use agreement.

Periodo di condivisione IPD

Starting March 2026 and available upon reasonable request

Criteri di accesso alla condivisione IPD

De-identified individual participant data will be available upon reasonable request from the corresponding author (turgayatay@gmail.com). Requests will be evaluated based on scientific merit and ethical considerations. Data will be shared after approval of a research proposal and signing of a data use agreement.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi